Literature DB >> 33787324

Dutch Outcome in Implantable Cardioverter-Defibrillator Therapy: Implantable Cardioverter-Defibrillator-Related Complications in a Contemporary Primary Prevention Cohort.

Marit van Barreveld1,2, Tom E Verstraelen1, Pascal F H M van Dessel3, Lucas V A Boersma1,4, Peter Paul H M Delnoy5, Anton E Tuinenburg6, Dominic A M J Theuns7, Pepijn H van der Voort8, Geert-Jan Kimman9, Erik Buskens10, Aeilko H Zwinderman2, Arthur A M Wilde1, Marcel G W Dijkgraaf2.   

Abstract

Background One third of primary prevention implantable cardioverter-defibrillator patients receive appropriate therapy, but all remain at risk of defibrillator complications. Information on these complications in contemporary cohorts is limited. This study assessed complications and their risk factors after defibrillator implantation in a Dutch nationwide prospective registry cohort and forecasts the potential reduction in complications under distinct scenarios of updated indication criteria. Methods and Results Complications in a prospective multicenter registry cohort of 1442 primary implantable cardioverter-defibrillator implant patients were classified as major or minor. The potential for reducing complications was derived from a newly developed prediction model of appropriate therapy to identify patients with a low probability of benefitting from the implantable cardioverter-defibrillator. During a follow-up of 2.2 years (interquartile range, 2.0-2.6 years), 228 complications occurred in 195 patients (13.6%), with 113 patients (7.8%) experiencing at least one major complication. Most common ones were lead related (n=93) and infection (n=18). Minor complications occurred in 6.8% of patients, with lead-related (n=47) and pocket-related (n=40) complications as the most prevailing ones. A surgical reintervention or additional hospitalization was required in 53% or 61% of complications, respectively. Complications were strongly associated with device type. Application of stricter implant indication results in a comparable proportional reduction of (major) complications. Conclusions One in 13 patients experiences at least one major implantable cardioverter-defibrillator-related complication, and many patients undergo a surgical reintervention. Complications are related to defibrillator implantations, and these should be discussed with the patient. Stricter implant indication criteria and careful selection of device type implanted may have significant clinical and financial benefits.

Entities:  

Keywords:  complications; implantable cardioverter‐defibrillator; inappropriate shocks; indication

Year:  2021        PMID: 33787324     DOI: 10.1161/JAHA.120.018063

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  2 in total

1.  Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register.

Authors:  Maria Concetta Pastore; Giulia Elena Mandoli; Alberto Giannoni; Giovanni Benfari; Frank Lloyd Dini; Nicola Riccardo Pugliese; Claudia Taddei; Michele Correale; Natale Daniele Brunetti; Erberto Carluccio; Anna Mengoni; Andrea Igoren Guaricci; Laura Piscitelli; Rodolfo Citro; Michele Ciccarelli; Giuseppina Novo; Egle Corrado; Annalisa Pasquini; Valentina Loria; Anna Degiovanni; Giuseppe Patti; Ciro Santoro; Luca Moderato; Alessandro Malagoli; Michele Emdin; Matteo Cameli; Gianmarco Rosa; Michele Magnesa; Pietro Mazzeo; Giuseppe De Carli; Michele Bellino; Giuseppe Iuliano; Ofelia Casciano; Simone Binno; Marco Canepa; Stefano Tondi; Mariantonietta Cicoira; Simona Mega
Journal:  Eur Heart J Open       Date:  2021-12-21

2.  Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology-A PROLONG-II Substudy.

Authors:  Johanna Mueller-Leisse; Johanna Brunn; Christos Zormpas; Stephan Hohmann; Henrike Aenne Katrin Hillmann; Jörg Eiringhaus; Johann Bauersachs; Christian Veltmann; David Duncker
Journal:  Sensors (Basel)       Date:  2022-03-05       Impact factor: 3.576

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.